retatrutide joint pain (Eli Lilly's triple GLP-1/GIP/Glucagon receptor agonist) just delivered the most impressive obesity + osteoarthritis data we've ever seen in the phase 3 TRIUMPH-4 trial: GLP1s & joint pain and

The list includes the development of methods to address nitrosamine impurities, improving the evaluation of complex drug-device combination products, and studying equivalence approaches for complex active ingredients

Gastrointestinal adverse events were again among the most frequently reported findings

The recommended dosage is two tablets daily

Yes, weight loss through healthy diet and regular physical activity can reduce risk for both conditions by improving insulin sensitivity and metabolic health

In rats, studies with dual amylin and calcitonin receptor agonists have demonstrated robust body weight loss, improved glucose tolerance and a decreased deposition of fat in liver tissue beyond what is observed after a body weight loss